In last trading session, Revance Therapeutics, Inc. (NASDAQ:RVNC) saw 1,333,486 shares changing hands with its beta currently measuring 1.65. Company’s recent per share price level of $25.5 trading at -$2.12 or -7.68% at ring of the bell on the day assigns it a market valuation of $1.68 Billion. That closing price of RVNC’s stock is at a discount of -35.76% from its 52-week high price of $34.62 and is indicating a premium of 53.8% from its 52-week low price of $11.78. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 495.7 Million shares which gives us an average trading volume of 547.63 Million if we extend that period to 3-months.
For Revance Therapeutics, Inc. (RVNC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.8. Splitting up the data highlights that, out of 11 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 10 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$1.03 in the current quarter.
Revance Therapeutics, Inc. (NASDAQ:RVNC) trade information
In the face of being in the red today for losing -7.68%, in the last five days RVNC remained trading in the green while hitting it’s week-highest on Friday, Oct 09 when the stock touched $28.90- price level, adding 11.76% to its value on the day. Revance Therapeutics, Inc.’s shares saw a change of 57.12% in year-to-date performance and have moved -6.01% in past 5-day. Revance Therapeutics, Inc. (NASDAQ:RVNC) showed a performance of -13.15% in past 30-days. Number of shares sold short was 4.38 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $37.36 to the stock, which implies a rise of 46.51% to its current value. Analysts have been projecting $23 as a low price target for the stock while placing it at a high target of $56. It follows that stock’s current price would jump +119.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -9.8% for stock’s current value.
Revance Therapeutics, Inc. (RVNC) estimates and forecasts
Statistics highlight that Revance Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +66.02% of value to its shares in past 6 months, showing an annual growth rate of 13.9% while that of industry is 13.9. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -7.3% in the current quarter and calculating -10.1% decline in the next quarter. This year revenue growth is estimated to rise 1449.6% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.77 Million for the same. And 8 analysts are in estimates of company making revenue of $4.66 Million in the next quarter that will end in December 01, 2020. Company posted $46Million and $89Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 3747.8% while estimating it to be 5136% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.5% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 6.9% while estimates for its earnings growth in next 5 years are of 11.6%
Revance Therapeutics, Inc. (NASDAQ:RVNC)’s Major holders
Insiders are in possession of 1.45% of company’s total shares while institution are holding 95.68% percent of that, with stock having share float percentage of 97.09%. Investors also watch the number of corporate investors in a company very closely, which is 200 institutions for Revance Therapeutics, Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at RVNC for having 4.44 Million shares of worth $108.41 Million. And as of June 29, 2020, it was holding 6.73% of the company’s outstanding shares.
The second largest institutional holder is JP Morgan Chase & Company, which was holding about 4.03 Million shares on June 29, 2020. The number of shares represents firm’s hold over 6.11% of outstanding shares, having a total worth of $98.36 Million.
On the other hand, Smallcap World Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 3291900 shares of worth $80.39 Million or 4.99% of the total outstanding shares. The later fund manager was in possession of 1.66 Million shares on June 29, 2020, making its stake of worth around $40.48 Million in the company or a holder of 2.51% of company’s stock.